In ∼50% of HER2+ breast cancers the PI3K/AKT pathway is altered as well, its hyperactivation leading to alternative pathways that lead to the development of drug resistance (Martorana et al., 2021). This evidence concerns the gene AKT1 and breast carcinoma.